Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Germline mutations in the TP53 gene

R A Eeles1

  • 1CRC Academic Unit of Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Surrey.

Cancer Surveys
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.

Psycho-oncology·2017
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Genetic variants associated with predisposition to prostate cancer and potential clinical implications.

Journal of internal medicine·2012
Same author

Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.

Human genetics·2011
Same journal

Future directions: bladder cancer.

Cancer surveys·2004
Same journal

Radiotherapy and chemotherapy for invasive bladder cancer.

Cancer surveys·2004
Same journal

The role of surgery in the multimodality treatment of bladder cancer.

Cancer surveys·2004
Same journal

Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy.

Cancer surveys·2004
Same journal

Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

Cancer surveys·2004
Same journal

Molecular biological changes in bladder cancer.

Cancer surveys·2004
See all related articles

Collaborative research is crucial for understanding rare TP53 gene mutations in Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like (LFL) families. Studies should focus on mutation-phenotype correlations, penetrance, and tailored screening and prevention strategies.

Area of Science:

  • Genetics
  • Oncology
  • Preventive Medicine

Background:

  • Germline mutations in the TP53 gene are predominantly found in Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like (LFL) families.
  • These genetic conditions are rare, necessitating collaborative research efforts.

Purpose of the Study:

  • To outline key areas for collaborative research concerning TP53 germline mutations.
  • To address the need for improved screening, understanding of disease progression, and treatment strategies for affected individuals.

Main Methods:

  • The abstract outlines proposed areas for collaborative study rather than detailing specific experimental methods.
  • These include correlating phenotypes with specific TP53 mutations, assessing age-specific penetrance, and cumulative cancer incidence.

Related Experiment Videos

Main Results:

  • The abstract does not present specific results but rather a framework for future research findings.
  • It highlights the potential for X-irradiation to induce DNA damage that is tolerated in individuals with TP53 mutations, suggesting a need for new screening methods.

Conclusions:

  • Collaborative studies are essential for advancing knowledge on TP53 mutations and their impact on cancer development.
  • Predictive testing and chemoprevention trials are recommended for LFS and LFL families to reduce cancer mortality.